Key result
RAS blockade reverses FK506-induced cardiac toxicity, reducing vacuolar degeneration scores vs FK506 alone.
Why the study?
The toxic effects of tacrolimus on the cardiovascular system at the histopathological level and the potential reversal by renin-angiotensin system blockade were investigated.
Does RAS blockade with quinapril or valsartan reverse tacrolimus-induced cardiovascular toxicity in a rat model?
Does RAS blockade with quinapril or valsartan reverse tacrolimus-induced cardiovascular toxicity in a rat model?
Blockade of the renin-angiotensin system with ACE inhibitors or ARBs can reverse histopathological signs of tacrolimus-induced cardiac toxicity in a rat model.
Answers are grounded in this paper and cite their sources.
Supports RAS blockade attenuating tacrolimus cardiotoxicity in rats; leaves open clinical translation.
INTRODUCTION: In this study, we investigate the toxic effects of tacrolimus (FK506) on the cardiovascular system at the histopathological level in a rat model and whether these effects can be reversed by the blockade of the renin-angiotensin system (RAS) by either an angiotensin-converting enzyme inhibitor (ACE-inhibitors) or an angiotensin receptor antagonist (ARB). METHODS AND RESULTS: Thirty-one Wistar rats were divided into four groups. FK506 group was treated with FK506 intraperitoneally (i.p.), FK506+ACE-inhibitors and FK506+ARB groups were treated with either quinapril or valsartan orally in addition to FK506. Control group was treated with saline i.p. Histological and immunohistochemical staining of cardiovascular tissue in the FK506 group showed increased vacuolar degeneration (11.2 vs. 5.8, p=0.008), arterial hyalinosis (10.7 vs. 6.3, p=0.036), transforming growth factor-beta (TGF-beta) (12.2 vs. 4.8, p=0.001) and vascular endothelial growth factor expression (VEGF) (10.7 vs. 6.3, p=0.036), elastic van Gieson (11.5 vs. 5.5, p=0.004), and periodic acid Schiff stain scores (12.5 vs. 4.5, p<0.001) compared to the control group. Immunohistochemical scores showed that expression of TGF-beta is up-regulated, and bone morphogenic protein (BMP-7) is down-regulated with FK506 toxicity. Adding RAS blockade with either an ACE-inhibitor or an ARB could reverse FK506 induced changes. Both FK506+ACE-inhibitors and FK506+ARB groups demonstrated decrease in arterial hyalinosis (22.1 vs. 14.4 (FK506+ACE-inhibitor) and 13.6 (FK506+ARB), p=0.09) and vacuolar degeneration (23.1 vs. 16.1 (FK506+ACE-inhibitor) and 12.4 (FK506+ARB), p=0.006) scores compared to the FK506 group. CONCLUSION: Blockade of RAS could reverse the histopathological signs of FK506 induced cardiac toxicity in a rat model.
No takes yet. Share an insight, caveat, or question.
Ağırbaşlı et al. (2007) studied Tacrolimus-related cardiovascular toxicity (n=31). Renin-angiotensin system (RAS) blockade (quinapril or valsartan) vs. FK506 (tacrolimus) alone was evaluated on Vacuolar degeneration score (p=0.006). Adding RAS blockade with an ACE-inhibitor or ARB reversed FK506-induced cardiac toxicity, significantly decreasing vacuolar degeneration scores compared to FK506 alone (16.1 and 12.4 vs 23.1; P=0.006).
Synapse has enriched 10 related papers. Consider them for comparative context: